SAO PAULO (Reuters) – A COVID-19 vaccine developed by China’s Sinovac Biotech was 78% effective in a late-stage Brazilian trial and entirely prevented severe cases, a source said on Thursday, boosting Chinese efforts to catch up with Western vaccine makers.

The reported results, closely watched by developing countries counting on the vaccine to begin mass inoculations, come after Turkish researchers said in December that the vaccine showed 91.25% efficacy based on interim data

Leave a Reply

Your email address will not be published. Required fields are marked *